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Mushroom
For
Improvement:
The Case for Psilocybin-Assisted Therapy
By Harry Justus

“I had a clear mind, it lifted the fog of depression. I could see my life, like a light in the tunnel.”
“I was lucid and alert, the depression had evaporated. It puts your head above the fog.”1

T

hese are quotes from individuals who underwent a
decidedly unconventional treatment for their depression: psychedelic-assisted psychotherapy.
Psychotherapy itself is a commonly-used treatment for depression,
with about 45% of Americans
diagnosed with major depression
receiving psychotherapy as a primary treatment method.2 However, the traditional combination of
psychotherapy and antidepressant
medication does not work for everyone, and certain patients have
depression that does not respond
to these forms of treatment. This
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is referred to as treatment-resistant
depression, which for this article
will be defined as a consistent,
professionally-diagnosed
score
of 17 or higher on the Hamilton
Depression Rating Scale (indicating at least moderate-to-severe
depression), and at least two failed
attempts at treating their depression with antidepressant medications during the current period
of depression.1 This article aims
to discuss the ways in which psychedelics affect the brain, the potential ways in which psychedelics
could be implemented as an aid in
psychotherapy, reasons why this

is a potentially beneficial research
area, and finally some potential
future steps toward a better understanding of the ways in which psychedelics could be a valuable tool
for the treatment of some mental
health disorders.
Wait— what’s a psychedelic?
Throughout history, humans have
used naturally-occurring chemical
compounds in a number of capacities, whether spiritual, therapeutic, or otherwise.3 Psychedelics
(meaning soul-revealing, from the
Greek words psyche— soul and
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deloun — to reveal) are a somewhat loosely-defined category of
consciousness-altering chemicals
which includes lysergic acid diethylamide (LSD, pictured above)
psilocybin, which is the active-ingredient in so-called “magic mushrooms,” (pictured below) and others.4 Psychedelics are chemically

similar to the neurotransmitter
serotonin, and have a strong effect on serotonin-2A receptors.
In other words, that means that
these chemicals affect various parts
of the brain in order to produce
profound shifts in our sensory
perceptions and in the ways we
think.5 However, in the past it was

difficult to research these chemicals much beyond their subjective
psychological effects— little was
known about the effects of psychedelics on the brain itself, only
the behavioral effects that could
be observed in people or animals
to whom these compounds were
administered.4 By the mid-1960s,
there had been a large number of
studies that showed a great deal of
potential for using psychedelics
as a therapeutic intervention for
mental health issues ranging from
depression to addiction, and even
end-of-life anxiety.5 These older
studies, while not up to the same
rigorous standards as modern ones,
provided a foundation of promising data upon which the modern
renaissance of psychedelic research
is based. Psychedelic research in
the United States was stalled when
psychedelics, increasingly associated with the counterculture movements of the 1950s and 1960s,

Some Other Controlled Substances:6
Schedule 1 (High risk of abuse and
addiction, no accepted medical uses):
Heroin, Cannabis (marijuana), peyote,
MDMA (Ecstasy).

Schedule III (Lower potential for
addiction than Schedule II, but still
potentially harmful): Ketamine, anabolic steroids, testosterone.

Schedule II (High risk of abuse,
some accepted medical uses): Vicodin,
Methamphetamine, Adderall, Ritalin,
fentanyl, cocaine.

Schedule IV (Lower potential for
addiction than schedule III): Xanax,
Ativan, Ambien, Valium, Tramadol.

were stigmatized and eventually
made illegal under the Controlled
Substances Act of 1970. The Controlled Substances Act designated
LSD and psilocybin as Schedule I
substances, which means that, according to the law, they have no
accepted medical use and a high
potential for addiction.6
In the past twenty years or
so, there has been a revitalization
of research into the psychotherapeutic potential of psychedelics.
This is due in large part to more advanced technology and techniques
that allow us to see with increasing clarity how exactly psychedelics affect our minds. For example,
many studies are now using modA brief history of psychedelics in
the 20th Century:4
1943 Albert Hofmann first discovers the conciousness-altering effects of
LSD
1947 Werner Stoll publishes first paper on these effects
1950 First English-language paper on
LSD published
1956 Term “psychedelic” first coined
1957 Term “magic mushrooms” first
coined
1958 Hofmann discovers the presence
of psilocybin as the main psychedelic
chemical in “magic mushrooms.”
1965 Sandoz, then the main manufacturer of psychedelic chemicals for
research in the US, stops synthesizing
LSD and psilocybin.
1966 Use of and research on psychedelics in the US begins to be suppressed.
1970 US President Richard Nixon
signs the Controlled Substances Act
into law, which designates LSD and
psilocybin as Schedule I substances.
This marks the end of research into
psychedelics in the US for the foreseeable future.
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ern brain imaging technologies
to see in real-time which parts of
the brain are being activated when
someone is under the influence of
a psychedelic chemical.8,9 This has
allowed for an entire new era of research that can begin to match the
intense subjective effects of psychedelics with the regions of the
brain that they appear to affect in
order to better understand exactly

!

What could psilocybin-assisted
psychotherapy look like?
Studies have been done to determine the most effective ways in which
psilocybin would be integrated into a psychotherapeutic setting. The
most common procedures involve two acute doses of psilocybin at two
separate testing times, usually about a week apart. Here is a timeline of
a potential treatment plan, compiled from recent studies whose results
show promise for the efficacy of psilocybin-assisted psychotherapy:1, 6 10

Before the First Dose

1

Participants undergo a battery of screenings in order to determine
mental and physical fitness for the study.

For

clarification purposes in the rest of this
article, unless otherwise
indicated, the term psychedelic will be used to refer to
both LSD and psilocybin, as
these have been the psychedelic
compounds that have received
the most attention for research.
However, this article is primarily about psilocybin and the case
for further research into its use
as a therapeutic tool to help
people with treatment-resistant
depression.

The aim of this article is not
to push for total legalization
of psychedelics. Far from it in
fact— these are chemicals that
have a powerful effect on the
brain, and thus should not be
taken lightly. Rather, this article
aims to encourage a reevaluation of the current scheduling
of psilocybin such that it could
be researched further as a potentially revolutionary tool for
helping individuals with treatment-resistant depression.
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The Dosing Sessions
9:00am Participants arrive at the testing facility and are tested for
alcohol, marijuana, and other drugs. This is followed by a quick
psychological testing session to ensure that there are no major deviations from the previously-gathered scores. Following successful
completion of these tests, participants are then brought into the
therapy room, where they are familiarized with the dosing environment and meet with the psychiatrists who will be supporting
them before, during, and after the dosing sessions.

Every half hour until 4:30pm Participants’ blood pressure and
heart rate are taken; psychiatrists make note of the apparent intensity of the participant’s experience. Psychiatrists also perform
check-ins with the participant to determine the current subjective
experience of the psilocybin— usually simply asking how they are
feeling.
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2

Participants meet with the psychiatrists running the study and undergo a brain
scan using an fMRI (functional magnetic resonance imaging), which will provide baseline levels of brain activity to which post-psilocybin brain activity can
be compared.

3
Participants undergo a lengthy preparation session with their assigned psychiatrist. This includes a long conversation with the psychiatrist wherein
the participant is encouraged to speak candidly about their life experiences,
including their own thoughts on how and why their depression originated.
Additionally, patients are exposed to some of the parts of the psilocybin-assisted psychotherapy session in order to familiarize themselves with the procedure, such as listening to selections of specially-chosen music with eye
shades on.

Throughout the dosing sessions: Supervising psychiatrists do not direct the
participant, instead allowing them to direct their own session, giving them the
freedom to immerse themselves in the experience without self-consciousness or
inhibition.

10:30am Patients receive their dose of psilocybin. In the first
session, they are given a low dose of 10 milligrams (mg) of psilocybin, which is meant to both familiarize the patient with the
subjective effects of psilocybin and also to assess how well the patient can tolerate the effects of the psilocybin. The second session
is the same, but the dosage of psilocybin is increased to 25mg.

Approx. 11:30am Subjective effects of psilocybin begin to manifest in the participants.
Approx. 12:30-1:30pm Participants experience peak psychedelic effects of psilocybin.

After the Dosing Sessions
6-7 hours post-dosing session Participants fill out a test that measures
their subjective experience of an altered state of consciousness.

One day post-25mg dose Participants are invited back to the testing facility to take the same battery
of tests that they underwent before
the first dosing session, including an
fMRI brain scan. Participants are
given the opportunity to debrief their
experience with the assisting psychiatrists.

One, two, three, and five weeks;
three months post-25mg dose
Participants take a follow-up test
that determines their current level
of depressive symptoms in order to
determine the extent to which (if
any) the psilocybin-assisted therapy
has affected their mental health.
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how and why these effects manifest.

Source (9)

The Case for Psilocybin-Assisted
Psychotherapy
How does it work?
As previously mentioned, psilocybin (and psychedelics in general)
have a very strong effect on serotonin receptors in the brain. Serotonin is involved in vision, hearing, and a variety of other cognitive
processes, meaning that psychedelics (as serotonin-like chemicals)
have pronounced effects on these
particular processes. To highlight
this, brain-imaging studies found
that LSD and psilocybin have a
significant effect on brain activity
in regions that are associated with
vision, hearing, and organized
thought. For a graphical representation of these changes in perception, see the above figure from
Carhart-Harris and colleagues9,
which provides a comparison of
the changes in perception and
thought between individuals who
had taken psilocybin compared to
a non-drug placebo. Clearly, psilocybin facilitates profound changes
in the way people experience the
world around them. It has been
proposed that this is one of the
main mechanisms by which psychedelics could help with treatment-resistant depression— many
patients with treatment-resistant
depression note that they often
get stuck in negative, circular
thought patterns. That is, they become bogged down in depressive
thoughts and cannot break free of
them. Since psilocybin so totally
alters the perception of thoughts
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and feelings, researchers think that
it can help the depressed patients
to break out of these oppressive
thought patterns and help them
see the world in a new way.1 To
quote one participant from a psilocybin-assisted
psychotherapy
study,

“my mind works differently
[now]. I ruminate much less,
and my thoughts feel ordered,
contextualized. Rumination was
like thoughts out of context, out
of time; now my thoughts feel
like they make sense, with context and logical flow.”1
Another study evaluated a group of
mentally healthy individuals who
were given varying doses of psilocybin, from a very low dose (almost
negligible) to a higher dose that is
around the same as the dose that
would be given in the second session of therapy as laid out above.11
These participants were then asked
to complete a series of tasks that
measured, among other things,
the experience of an altered state

of consciousness. The researchers
found that there were several shifts
in the participants’ perception of
their consciousness, notably in the
feeling of “oceanic boundlessness,”
which indicates a feeling of being
connected to everything around
oneself— as though they were one
with the world around them.11
This corroborates the subjective
accounts of the psilocybin experience in another study, which notes
a major shift in its participants’
attitudes from feelings of disconnection with the world around
them to feeling more connected
to themselves, their emotions, and
the world around them.1 Another way in which it has been proposed that psychedelics in general
change brain function to combat
depression is through increasing
what is called cortical entropy.
Essentially, cortical entropy is an
increase in random activity in the
brain, allowing for communication between brain regions that
are normally not associated.12 Increased cortical entropy has been
linked with the personality trait of
openness to experience, which is
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in line with the idea that psychedelics may help combat depression
by aiding the individual in acquiring a new interpretation of the
world around them and their own
thoughts.1,12
Hold on, is this even safe?
Remember, this article is not written in support of recreational psychedelic use. The aim of this article is to provide support for the
stance that psychedelics have the
potential to be an effective tool in
treating depression. Research has
shown that psychedelics are actually quite safe physically, as they
do not build tolerance easily and
doses that could cause any lasting
physiological harms are substantially higher than any dose that
would be administered in a clinical setting.11 Psychedelics also have
not been shown to cause mutations
in cells, which are a precursor for
many negative health outcomes.13
Moreover, psychedelics have less of
a permanent effect than MDMA
(which has been considered for
treating some psychiatric disorders) on the brain’s ability to use
the serotonin that it produces naturally, which means that psychedelics may be less harmful for use
in the long-term than other proposed drug therapies.14 One study
of a large sample of the US population found that people who had
used psychedelics at some point
in their lives experienced lower
rates of psychological distress and
suicidal behavior.15 It is, however,
important to note that psilocybin
and other psychedelics can have
some potential adverse effects. In

fact, psychedelics have been used
in some studies to model psychotic states; hence the importance of
screening out patients in danger of
having a psychotic episode as a result of their use.16 One study found
that some patients experience
fleeting anxiety while undergoing
the psychedelic experience.11 That
said, research shows that as long
as the participants are adequately
screened, prepared, and taken care
of during the treatment sessions,
none of these negative effects last
beyond the dosing sessions. Moreover, it appears that the physical effects of psychedelics do not
cause any lasting physical health
issues in well-prepared users.11 Additionally, in the unanimous opinion of the twenty participants in
one study, the psilocybin-assisted
treatment was preferable to any
previous form of therapy for their
depression.
Moving Forward
Current Limitations
Psychedelics are still not well-understood compared to other drugs,
and have received an unsavory image in many countries due to their
legal status and portrayals in popular media as being used mainly
by less-than-reputable individuals.
As such, there are many misconceptions about psychedelics that
must be dispelled if they are to be
legalized and publicly accepted for
research in the US (or anywhere
else in the world). The key to
this will be education about these
chemicals. It is important to note
that any proposed psychedelic-assisted therapies do not call for sim-

ply handing the patient a powerful
mind-altering substance and simply hoping for the best; remember,
the patients are monitored closely and work with highly-trained
mental health professionals at every step of the process, especially during the period where the
patient is experiencing the acute
physiological and psychological effects of these substances.1
Possible Future Steps
The first institutional step towards
the implementation of psychedelic-assisted therapies is lifting
restrictions that keep these chemicals from being researched in a way
that could produce more powerful
results than previous studies. The
current group of studies, while important and vital to the furthering
of this research area, all have very
small sample sizes— usually fewer
than twenty people, and often fewer than ten. Recent studies indicate
that psychedelics (at the very least
LSD and psilocybin) are safe to administer in well-controlled clinical
environments, which for now are
the only environments in which
these studies should be taking
place to begin with. Additionally,
psychedelics have been considered
for use as a way to better understand the neurological bases of
other mental illnesses like schizophrenia, as some of the effects of
psychedelics (such as hallucinations) are similar to those observed
in patients with these illnesses.17
In the future, with more data and
less limiting laws on research, psilocybin-assisted therapies have the
potential to be used in a variety
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of clinical settings. These include
therapies to treat end-of-life anxiety, alcohol and tobacco addiction, and obsessive-compulsive
disorder, among others.18,19 Additionally, new studies are beginning
to look at other illegal or highly
restricted substances like MDMA
(ecstasy) and ketamine for use in
treating depression, post-traumatic stress disorder, addiction, and
others.20, 21
In sum, I believe the most
important point to take away from
this article is that psychedelics
(especially psilocybin) are worth
researching, because they could
provide new and effective ways
to treat otherwise treatment-resistant mental health disorders. They
have already shown a great deal of
promise— if psychedelics could
be the way for a chronically-depressed person to finally get above
that fog of incessant rumination
and despair, then they are absolutely worth researching.
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